Psychiatric Times Experts Weight in on FDA Advisory Decision for PTSD
A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.
Watch
Adolescent Patient with ADHD: Patient Case 2
Panelists discuss how 17-year-old patients challenges with inattention, anxiety, and executive dysfunction ahead of college highlight the importance of balancing pharmacologic and non-pharmacologic ADHD treatments while addressing concerns about stimulant use and medication diversion.
Watch
Treatment Adherence Challenges in ADHD
Panelists discuss how treatment adherence in ADHD patients is often impacted by forgetfulness and misconceptions, and how using tools like pill organizers can significantly improve consistency and outcomes.
Watch
Monitoring Treatment Response in Narcolepsy
July 14th 2025Panelists discuss the importance of setting realistic expectations when initiating pitolisant for narcolepsy, emphasizing consistent daily use, gradual titration, and patient-centered measures of success, while accounting for external stressors, lifestyle factors, and the need for occupational accommodations to support long-term functional outcomes.
Watch
Lifestyle and Behavioral Interventions in Narcolepsy
July 14th 2025Panelists discuss how behavioral strategies—including structured sleep routines, scheduled naps, dietary adjustments, light therapy, and cognitive behavioral support—are essential components of comprehensive narcolepsy management, reinforcing that individualized, nonpharmacologic interventions can significantly improve daily function and long-term outcomes.
Watch
Clinicians’ Experience with ADHD Treatments
Panelists discuss how viloxazine fits into both pediatric and adult ADHD treatment plans, especially as a non-stimulant option for patients with complex cases or concerns about stimulant side effects, while emphasizing flexible dosing and caregiver involvement.
Watch
Viloxazine for ADHD in Children and Adolescents
Panelists discuss how recent clinical studies on viloxazine in children and adolescents demonstrated early symptom improvement, dose-dependent efficacy, and tolerability, with the most benefit seen at 400 mg in those aged 11 and under.
Watch
Role of Pitolisant in Management of Narcolepsy
July 7th 2025Panelists discuss the clinical and practical advantages of pitolisant for patients with frequent cataplexy and concerns about controlled substances, highlighting its dual efficacy, favorable safety profile, and flexible dosing as key features that support a patient-centered, stigma-conscious approach to narcolepsy care.
Watch
Patient Education and Shared Decision-Making in Narcolepsy
July 7th 2025Panelists discuss the importance of shared decision-making in narcolepsy care, emphasizing structured conversations that explore patient goals, treatment preferences, and concerns—while navigating practical barriers like insurance—so that therapy selection is personalized and collaborative, often requiring a multimodal approach for optimal outcomes.
Watch
A Case of a 32-Year-Old Male With Type 1 Narcolepsy
June 30th 2025Panelists discuss the critical importance of early diagnosis and personalized treatment in narcolepsy, using a case study to illustrate how tailored therapy—considering patient preferences, comorbidities, and lifestyle factors—can improve engagement, safety, and long-term outcomes.
Watch
Current State of Treatment Landscape and Unmet Needs in Narcolepsy Management
June 30th 2025Panelists discuss the evolving treatment landscape for narcolepsy, highlighting the growing availability of personalized therapies, persistent challenges with diagnosis and access, and the importance of clinician advocacy and education to ensure timely, individualized care for patients.
Watch